Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 20/20 | 1.00 |
| ▸ | NOS3 | P29474 | 18/20 | 1.00 |
| ▸ | NOS2 | P35228 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21067846 | 1.00 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| Bromide SCHEMBL11804676 | 0.98 | NOS1 (0.96) | NOS1NOS3NOS2 | |
| Iodide SCHEMBL11683524 | 0.98 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| SCHEMBL1387463 | 0.85 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| Iodide SCHEMBL7787922 | 0.84 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| SCHEMBL1387538 | 0.82 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| SCHEMBL7788121 | 0.82 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| SCHEMBL7982056 | 0.81 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| SCHEMBL1387417 | 0.81 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| SCHEMBL1387587 | 0.80 | NOS1 (1.00) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-H09504278-A | — | — | 1997-04-28 | — | — | JP | claimed |
| EP-0723438-A1 | SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-07-31 | — | — | EP | claimed |
| WO-1995009619-A2 | SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-13 | — | — | WO | claimed |
| US-20150148317-A1 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS | INVIVO THERAPEUTICS CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
| US-20130324509-A1 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS | INVIVO THERAPEUTICS CORPORATION (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130324500-A1 | SPINAL CORD INJURY, INFLAMMATION AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS | INVIVO THERAPEUTICS CORPORATION (US) | 2013-12-05 | — | — | US | disclosed |
| CN-102858353-A | Spinal cord injury, inflammation, and immune-disease: local controlled release of therapeutic agents | INVIVO THERAPEUTICS CORP | 2013-01-02 | — | — | CN | disclosed |
| US-20100196481-A1 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS | INVIVO THERAPEUTICS CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| WO-2002020834-A2 | METHOD FOR THE IDENTIFICATION OF GENES THAT ARE INVOLVED IN THE MODULATION OF A POPTOSIS IN CELLS | EIRX THERAPEUTICS LIMITED (IE) | 2002-03-14 | — | — | WO | disclosed |
| US-20010034342-A1 | Substituted urea and isothiourea derivatives as no synthase inhibitors | OPLINGER JEFFREY ALAN (US) | 2001-10-25 | — | — | US | disclosed |
| US-6297276-B1 | Substituted urea and isothiourea derivatives as no synthase inhibitors | GLAXOSMITHKLINE | 2001-10-02 | — | — | US | disclosed |
| US-6225305-B1 | Substituted urea and isothiorea derivatives as no synthase inhibitors | GLAXO WELLCOME INC. | 2001-05-01 | — | — | US | disclosed |
| US-6090846-A | ADMINISTERING S-ETHYL-N-((4-TRIFLUOROMETHYL)PHENYL)ISOTHIOUREA | GLAXO WELLCOME INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-5837718-A | ANTIHISTAMINES | SEED CAPITAL INVESTMENT (SCI) B.V. (NL) | 1998-11-17 | — | — | US | disclosed |
| EP-0573542-B1 | IMIDAZOLE-DERIVATIVES HAVING ANTAGONISTIC ACTIVITY ON THE HISTAMINE H3-RECEPTOR | SEED CAPITAL INVESTMENTS (NL) | 1997-10-15 | — | — | EP | disclosed |
| EP-0723438-A1 | SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995009619-A2 | SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-13 | — | — | WO | disclosed |
| EP-0573542-A1 | IMIDAZOLE-DERIVATIVES HAVING AGONISTIC OR ANTAGONISTIC ACTIVITY ON THE HISTAMINE H 3?-RECEPTOR. | SEED CAPITAL INVESTMENTS (NL) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992015567-A1 | IMIDAZOLE-DERIVATIVES HAVING AGONISTIC OR ANTAGONISTIC ACTIVITY ON THE HISTAMINE H3-RECEPTOR | SEED CAPITAL INVESTMENT (SCI) B.V. (NL) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034342-A1 | Substituted urea and isothiourea derivatives as no synthase inhibitors | NOS1, NOS2, SLC14A1 | NOS1 1/4885NOS3 4/4885NOS2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.